Status:
COMPLETED
Impact of Antioxidant Treatment on DNA Fragmentation Index
Lead Sponsor:
Region Skane
Collaborating Sponsors:
Q-Pharma
Octean
Conditions:
Male Infertility
Eligibility:
FEMALE
18-50 years
Phase:
NA
Brief Summary
Increased sperm DNA Fragmentation Index implies decreased male fertility in vivo and in vitro. There is need for developing new strategies for improvement of male fertility. The study aims to investig...
Detailed Description
In the Western world, approximately 15-20% of couples experience infertility problems during their reproductive life. In this context ´'infertility' is defined as 12 months of unprotected intercourse ...
Eligibility Criteria
Inclusion
- Referred due to infertility
- Age: 18-50 years,
- Non-smoking,
- Sperm DNA Fragmentation Index \>25%
Exclusion
- Body mass index (BMI) ≥30,
- FSH outside the normal range of 2-8 IU/L,g)
- LH outside the normal range of 2-10 IU/L,
- T \< 10nmol/L
- Treated with antihypertensive drugs, hormones, statins, psychotropic drugs, or oral cortisone for the last six months,
- History of anabolic steroids use,
- Taking antioxidant supplementation the last six months.
Key Trial Info
Start Date :
July 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2016
Estimated Enrollment :
79 Patients enrolled
Trial Details
Trial ID
NCT03466229
Start Date
July 1 2015
End Date
December 31 2016
Last Update
March 16 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.